Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish. (28th June 2022)

• Record Type: Journal Article
• Authors: Ren, Qingyu; Jiang, Xin; Paudel, Yam Nath; Gao, Xin; Gao, Daili; Zhang, Pengyu; Sheng, Wenlong; Shang, Xueliang; Liu, Kechun; Zhang, Xiujun; Jin, Meng
• Is Part Of: Journal of ethnopharmacology. Volume 292(2022)
• Publication Date: 2022-06-28
• Subjects: Parkinson's disease -- MPTP -- α-synuclein -- Toll-like receptor-4; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2022.115234
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Parkinson's disease (PD) is the second most devastating age-related neurodegenerative diseases after Alzheimer diseases (AD) and is characterized by the loss of dopaminergic (DA) neurons in the substantia nigra (SN) and aggregation of α-synuclein ( α-syn ). The precise etiology of PD is not yet fully understood and lacks the disease-modifying therapeutic strategies that could reverse the ongoing neurodegeneration. In the quest of exploring novel disease modifying therapeutic strategies, natural compounds from plant sources have gained much attention in recent days. Glycyrrhizin (GL) is the main active ingredient of the roots and rhizomes of licorice ( Glycyrrhiza glabra L), which are generally used in the treatment of inflammatory diseases or as a tonifying herbal medicine. In Persia, GL is a conventional neuroprotective agent that are used to treat neurological disorders. The traditional use of GL in Japan is to treat chronic hepatitis B. In addition, GL is a natural inhibitor of high mobility group box 1 (HMGB1) which has exerted neuroprotective effect against several HMGB1 mediated pathological conditions. Aim of the study: The study is aimed to evaluate therapeutic effect of GL against PD in zebrafish. Material and methods: PD in zebrafish larvae is induced by administration of neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Apoptosis was assessed with TUNEL assay. Gene expression was performed to assess the modulation in genes related to neuroinflammatory and autophagy. Results: We observed that GL co-treatment increased the length of DA neurons, decreased the number of apoptotic cells in zebrafish brain, and inhibited the loss of vasculature and disorganized vasculature induced by MPTP. GL co-treatment relieved the MPTP-induced locomotor impairment in zebrafish. GL co-treatment suppressed MPTP-induced upregulated mRNA expression of inflammatory markers such as hmgb1a, tlr4b, nfκb, il1β, and il6. GL co-treatment suppressed the autophagy related genes α-syn and atg5 whereas increased the mRNA expression level of parkin and pink1 . In addition, molecular docking study reveals that GL has binding interaction with HMGB1, TLR4, and RAGE. Conclusion: Hence, the effect of GL co-treatment on MPTP-induced PD-like condition in zebrafish is to alleviate apoptosis and autophagy, as well as suppress inflammatory responses. Graphical abstract: Image 1 Highlights: GL co-treatment ameliorates MPTP-induced PD like condition in zebrafish. GL anti-PD effect might be mediated by its regulation in inflammation and autophagy. Molecular docking reveals the interaction of GL with HMGB1, TLR4, and RAGE.